Gilde Healthcare
Investor profile
Venture capital
Also recorded as: Gilde Healthcare Partners
Deals
19
distinct rounds
Companies
15
backed
Active span
2005–2025
21 yrs
Total round €
€812M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Ysios Capital5
- GIMV4
- Lightstone Ventures4
- New Enterprise Associates4
- Forbion3
- INKEF Capital3
- Medtronic3
- Novo Holdings3
- Polaris Partners3
- Seventure Partners3
- Sofinnova Partners3
- Andera Partners2
- Asabys Partners2
- IDInvest Partners2
- Invus2
- Ireland Strategic Investment Fund2
- Jeito Capital2
- Novartis Venture Fund2
- UCB Ventures2
- UPMC Enterprises2
- Abbvie Biotech Ventures1
- Amadeus Capital Partners1
- Atlantic Bridge1
- Boehringer Ingelheim Venture Fund1
- Bpifrance1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Fire1 | Ireland | 3 | €179M |
| SpliceBio | Spain | 2 | €168M |
| Noema Pharma | Switzerland | 2 | €135M |
| ProVerum | Ireland | 1 | €69M |
| WiThings | France | 1 | €51M |
| Breath Therapeutics | Germany | 1 | €44M |
| Sanifit | Spain | 1 | €37M |
| STAT-Diagnostica | Spain | 1 | €25M |
| Symphogen | Denmark | 1 | €23M |
| Calypso Biotech | Netherlands | 1 | €20M |
| Nyxoah | Belgium | 1 | €18M |
| NightBalance | Netherlands | 1 | €13M |
| AM-Pharma | Netherlands | 1 | €12M |
| Draupnir Bio | Denmark | 1 | €12M |
| Qinec | UK | 1 | €7.2M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| SpliceBio | Series B | €118M | 2025-06 |
| Fire1 | Other | €116M | 2025-01 |
| Noema Pharma | Series B | €106M | 2023-03 |
| ProVerum | Series B | €69M | 2025-08 |
| WiThings | Series B | €51M | 2020-07 |
| SpliceBio | Series A | €50M | 2022-02 |
| Breath Therapeutics | Series A | €44M | 2017-02 |
| Fire1 | Series C | €40M | 2017-12 |
| Sanifit | Series C | €37M | 2015-08 |
| Noema Pharma | Series B | €29M | 2024-12 |